Lotus Eye Hospital And Institute Limited (LOTUSEYE)

Loading page…

Lotus Eye Hospital And Institute Limited (LOTUSEYE) · mywealthgrid

About

Lotus Eye Hospital And Institute Limited operates eye-care hospital facilities serving the Indian healthcare market. With a market capitalisation of ₹240.93 crore and recent quarterly revenue of ₹17.06 crore (Jun 2026), the company is a mid-sized provider of specialised eye care services.

Face value: ₹10

Market cap

₹241 Cr

P/E

1,604.1×

P/B

4.0×

Dividend yield

ROE

0.1%

ROCE

1.2%

Debt / equity

0.19

OPM

6.3%

EPS (TTM)

₹0.1

Book value

₹28.9

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Extreme valuation at PE of 1,606 reflects historically low earnings power; verify if recent profitability is sustainable or a temporary rebound.
Profit volatility: net profit swung from -₹0.32 Cr (Mar 2026) to +₹0.61 Cr (Jun 2026) in consecutive quarters; establish causes of margin swings from 3.53% to 17.35% OPM.
Poor capital efficiency: ROE of 0.13% is among the lowest; assess whether capital is trapped in slow-turning assets or reflects structural margin weakness.
Minimal institutional conviction: FII at 0% and DII at 0.02% suggest sophisticated investors see material risks; identify what due diligence concerns exist.

Generated analysis · source review pending

Growth drivers

Recent revenue acceleration: June 2026 quarter achieved ₹17.06 Cr, 26% above March 2026; verify if this reflects consistent demand growth or seasonal/one-time factors.
Operating margin expansion: OPM jumped to 17.35% in June 2026 from 3.53% in March 2026; verify which cost lines improved and whether margins can sustain.
Profitability recovery: June 2026 net profit of ₹0.61 Cr follows two quarters of losses (Mar -₹0.32 Cr, Dec -₹0.26 Cr); verify whether this recovery reflects volume growth, operational improvements, or cyclical factors.

Generated analysis · source review pending

2,504 historical price candles were omitted because the exchange source has not been verified.

₹115.0+1.5%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of 2.1% (3-yr avg)
−Thin operating margin of 6.3%
−Profit declined 44.9% a year over the last 5 years
−Weak interest coverage of 0.9×
−Expensive at 1604.1× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

26/100

Business quality: 19
Growth: 42
Valuation

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	31	9	9	38	41	32	39	47	48	50	54
COGS	-9	4	4	11	12	10	12	15	15	15	17
Gross profit	—	5	5	27	29	23	27	32	33	34	37
	41	5	5	24	25	19	21	24	26	31	34
	-1	-0	-0	3	4	4	6	8	7	3	3
OPM %	-1.7%	-5.3%	-5.3%	8%	9.4%	11%	15%	16.1%	13.6%	6.9%	6.3%
Depreciation	—	1	1	3	3	2	3	3	4	3	4
Interest	0	0	0	0	0	0	0	0	0	0	1
	1	0	0	1	0	1	1	1	1	1	1
Profit before tax	-0	-1	-1	1	1	2	4	6	4	1	-0
Tax	-0	-0	-0	-0	0	0	1	2	1	1	-0
Tax %	-600%	-26.5%	-26.5%	-12.7%	26.7%	21.6%	27.1%	27.8%	27.4%	46.4%	-260%
	0	-1	-1	1	1	2	3	4	3	1	0
PAT margin %	0.3%	-9.9%	-9.9%	1.9%	2.6%	4.9%	7.7%	8.7%	6%	1.5%	0.2%
EPS (₹)	0.1	-0.4	-0.4	0.3	0.5	0.5	0	2	1.4	0.4	0
EPS adjusted (₹)	0.1	-0.4	—	—	0.5	0.8	1.4	2	1.4	0.4	0
	0%	—	—	0%	0%	98%	—	25.5%	0%	0%	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	21	21	21	21	21	21	21	21	21
Reserves	29	29	—	32	34	37	39	39	39
	0	0	—	0	0	0	0	0	11
	5	5	—	7	7	6	7	10	11
Total equity & liabilities	55	55	—	59	62	63	67	70	83
	44	41	43	41	44	44	49	54	66
CWIP	0	1	—	—	—	0	0	0	0
Investments	—	—	—	0	0	0	0	0	0
	11	13	—	19	18	19	18	16	17
Total assets	55	55	—	59	62	63	67	70	83

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	71%	70.7%	69.8%	68.8%	68.2%	68.2%	68.8%	69%
EBITDA margin %	8%	9.4%	11%	15%	16.1%	13.6%	6.9%	6.3%
EBIT margin %	0.1%	3.2%	3.8%	8.6%	9.8%	5.8%	0.9%	-0.7%
PAT margin %	1.9%	2.6%	4.9%	7.7%	8.7%	6%	1.5%	0.2%
Working capital
Receivable days	—	—	8	6	9	10	10	8
Inventory days	—	—	66	70	68	76	90	84
Payable days	—	—	106	107	77	82	79	71
NWC days	—	—	-31	-32	0	4	21	21
Leverage
Current ratio	—	—	2.34	2.23	2.83	2.25	1.56	1.22
Debt to EBITDA	—	—	0	0	0	0	0	3.38
Debt to equity	—	—	0	0	0	0	0	0.19
Interest coverage	11.7	31.6	32.8	32.6	57.5	41.1	4.8	0.9
Asset turnover	—	—	0.55	0.63	0.74	0.72	0.71	0.65
Return ratios
Return on assets %	—	—	2.7%	4.8%	6.5%	4.4%	1.1%	0.1%
Return on capital employed %	—	—	3.7%	7.8%	10.1%	6.9%	2.8%	1.2%
Return on equity %	—	—	3%	5.5%	7.1%	4.9%	1.2%	0.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	57.58%	56.58%	41.4%	40.24%	40.03%	40.14%	40.22%	40.39%	40.64%	40.67%	40.14%	40.14%
	0%	0%	0%	0%	0%	0%	0%	0.01%	0%	0.01%	0%	0%
	0%	0%	0%	0.01%	0.03%	0.04%	0.04%	0.02%	0.02%	0.02%	0.02%	0.02%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	42.42%	43.42%	58.6%	59.75%	59.94%	59.82%	59.74%	59.58%	59.34%	59.3%	59.84%	59.84%
No. of shareholders	—	—	—	—	—	—	—	—	10,777	10,240	9,939	9,627

Promoter holding down 17.44 percentage points since Sep 2023.

63 deals · 16 Jun 2022 – 1 Sept 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
1 Sept 2025	. THOMAS SANTOSH	Bulk	NSE	Buy	1,24,682	₹123.94	₹1.55 Cr
18 Mar 2025	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Buy	1,13,269	₹58.07	₹0.66 Cr
20 Aug 2024	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Buy	2,00,409	₹80.60	₹1.62 Cr
13 Aug 2024	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Sell	2,01,590	₹77.11	₹1.55 Cr
13 Aug 2024	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Buy	2,01,590	₹74.11	₹1.49 Cr
13 Aug 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	1,26,566	₹76.57	₹0.97 Cr
13 Aug 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	1,26,566	₹76.46	₹0.97 Cr
12 Jul 2024	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Buy	1,31,328	₹65.27	₹0.86 Cr
12 Jul 2024	. VRAMATH FINANCIAL SERVICES PVT LTD	Bulk	NSE	Sell	31,328	₹68.94	₹0.22 Cr
11 Mar 2024	RAJEEV CHOUDHARY	Bulk	NSE	Buy	1,20,000	₹66.20	₹0.79 Cr

1–10 of 63

1 / 7

Ms. Sundaramoorthy KavethaNon-Executive - Non Independent Director-Chairperson related to Promoter
Ms. Sundaramoorthy SangeethaExecutive Director-MD
Mr. Kuttapalayam Ramalingam SongappanNon-Executive - Non Independent Director
Mr. Senagounder NatesanNon-Executive - Independent Director
Mr. Gopalakrishnan Karthik VeeramaniNon-Executive - Independent Director
Mr. Perumalsamy MahendranNon-Executive - Independent Director
Mr. Ramanujam ReghunathanChief Finanacial Officer
Mr. Prathish SCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Lotus Eye Hospital And Institute Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

5

Final dividend18 Sept 2023 · ex-date₹0.5
Final dividend8 Sept 2022 · ex-date₹0.5
Final dividend8 Sept 2021 · ex-date₹0.5
Dividend dividend14 Sept 2018 · ex-date₹0.5
Dividend dividend2 Aug 2017 · ex-date₹0.5

1

Board meeting to consider results10 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

19 announcementsExport CSV

1 Sept 2026, 5:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	71%	70.7%	69.8%	68.8%	68.2%	68.2%	68.8%	69%
EBITDA margin %	8%	9.4%	11%	15%	16.1%	13.6%	6.9%	6.3%
EBIT margin %	0.1%	3.2%	3.8%	8.6%	9.8%	5.8%	0.9%	-0.7%
PAT margin %	1.9%	2.6%	4.9%	7.7%	8.7%	6%	1.5%	0.2%
Working capital
Receivable days	—	—	8	6	9	10	10	8
Inventory days	—	—	66	70	68	76	90	84
Payable days	—	—	106	107	77	82	79	71
NWC days	—	—	-31	-32	0	4	21	21
Leverage
Current ratio	—	—	2.34	2.23	2.83	2.25	1.56	1.22
Debt to EBITDA	—	—	0	0	0	0	0	3.38
Debt to equity	—	—	0	0	0	0	0	0.19
Interest coverage	11.7	31.6	32.8	32.6	57.5	41.1	4.8	0.9
Asset turnover	—	—	0.55	0.63	0.74	0.72	0.71	0.65
Return ratios
Return on assets %	—	—	2.7%	4.8%	6.5%	4.4%	1.1%	0.1%
Return on capital employed %	—	—	3.7%	7.8%	10.1%	6.9%	2.8%	1.2%
Return on equity %	—	—	3%	5.5%	7.1%	4.9%	1.2%	0.1%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Max Healthcare Institute LimitedMAXHEALTHMAXHEALTH	₹91,573 Cr	₹95,052 Cr	₹8,712 Cr	₹2,318 Cr	26.8%	₹1,457 Cr	17.2%	13.8%	14.3%	-110
Manipal Health Enterprises LimitedMANIPALHOSMANIPALHOS	₹91,552 Cr	₹1,02,105 Cr	₹10,336 Cr	₹2,611 Cr	25.3%	₹917 Cr	8.9%	12.5%	12.8%	38
Fortis Healthcare LimitedFORTISFORTIS	₹59,268 Cr	₹62,140 Cr	₹9,506 Cr	₹2,131 Cr	22.8%	₹1,048 Cr	11.7%	13%	11.1%	-99
Aster Dm Healthcare LimitedASTERDMASTERDM	₹36,728 Cr	₹37,429 Cr	₹4,876 Cr	₹958 Cr	19.4%	₹319 Cr	9.2%	11.9%	9.7%	-112
Global Health LimitedMEDANTAMEDANTA	₹36,498 Cr	₹37,688 Cr	₹4,683 Cr	₹979 Cr	20.8%	₹556 Cr	12.6%	16.9%	15.1%	-26
Narayana Hrudayalaya Ltd.NHNH	₹35,594 Cr	₹40,460 Cr	₹9,072 Cr	₹1,749 Cr	20.5%	₹816 Cr	10.2%	15.1%	19.7%	-181
Krishna Institute Of Medical Sciences LimitedKIMSKIMS	₹29,457 Cr	₹32,701 Cr	₹4,213 Cr	₹833 Cr	20.5%	₹205 Cr	6.2%	9.5%	11%	-50
Dr. Agarwal's Health Care LimitedAGARWALEYEAGARWALEYE	₹15,420 Cr	₹15,578 Cr	₹2,207 Cr	₹612 Cr	27.4%	₹148 Cr	8.1%	10.1%	6.8%	-76
Rainbow Childrens Medicare LimitedRAINBOWRAINBOW	₹13,003 Cr	₹13,003 Cr	₹1,820 Cr	₹575 Cr	32%	₹285 Cr	16.5%	18.2%	17.9%	-73
Park Medi World LimitedPARKHOSPSPARKHOSPS	₹11,696 Cr	₹11,924 Cr	₹1,679 Cr	₹444 Cr	26.5%	₹258 Cr	16.3%	21.4%	16.7%	-2
Healthcare Global Enterprises LimitedHCGHCG	₹9,984 Cr	₹10,895 Cr	₹2,627 Cr	₹480 Cr	18.3%	₹23 Cr	0.9%	9.1%	1.2%	-93
Yatharth Hospital & Trauma Care Services LimitedYATHARTHYATHARTH	₹9,965 Cr	₹10,218 Cr	₹1,334 Cr	₹310 Cr	24.2%	₹174 Cr	14.1%	12.3%	10%	-26

Date	Category	Subject	Filing
1 Sept 2026, 5:07 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
1 Sept 2026, 1:02 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
1 Sept 2026, 12:50 pm	AGM/EGM AGM	29Th Annual General Meeting Of The Company - September 23, 2026	PDF
27 Aug 2026, 3:24 pm	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release	PDF
11 Aug 2026, 2:34 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
10 Aug 2026, 7:41 pm	Result Financial Results	Results - Standalone Unaudited Financial Results For The Quarter Ended June 30, 2026	PDF
10 Aug 2026, 6:38 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Standalone Unaudited Financial Results For The Quarter Ended June 30, 2026	PDF
1 Aug 2026, 12:36 pm	Board Meeting	Board Meeting Intimation For Consideration And Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2026	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3	3	6	4	5	3	4	4	6	5	3
	-1	-1	-4	-4	-1	0	-4	-2	-5	-4	-12
	-1	-0	-2	-1	0	-0	-2	-2	-3	-2	9
Net cash flow	—	—	—	—	—	3	-1	0	-2	-1	-0
Free cash flow	2	2	2	-0	2	2	-0	1	0	0	-10
CFO / Operating profit %	—	—	—	136.4%	126.3%	77%	75%	57.9%	86.9%	143.9%	92.9%

Lotus Eye Hospital And Institute Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

5

1

Announcements

Not in the F&O segment

No fund holdings on record

5

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Lotus Eye Hospital And Institute Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Dividends5

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Dividends5

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

5

1

5

1